Volume 34, Issue 3 (11-2010)                   Research in Medicine 2010, 34(3): 187-190 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jam H, Bolouri N, Jafari M, Rakhshan A, Raie M R, Solat F et al . Evaluation of Immunoreactivity of cellular markers of CD15 nad CD30 among patients with classic Hodgkin’s lymphoma. Research in Medicine. 2010; 34 (3) :187-190
URL: http://pejouhesh.sbmu.ac.ir/article-1-789-en.html
Department of Pathology, Shohadaye- Tajrish Hospital, Shahid Beheshti University (M.C), Tehran, Iran , afshinmo2002@yahoo.com
Abstract:   (14762 Views)
Abstract Background: Hodgkin's lymphoma (HL) is a curable lymphoid malignancy. Different Immunohistochemical markers specially CD15 & CD30 are used to diagnose HL and differentiate it from other lymphomas including anaplastic large cell lymphoma (ALCL) regarding different reports on the frequency of immunoreactivity for these markers in the literature and lack of information in this regard in Iran, this study is carried out in Iranian Hodgkin’s lymphoma patients to determine the frequency of these markers in Iranian HL patients. Methods: A cross sectional study is carried out on all patients with definite diagnosis of classic Hodgkin’s lymphoma in studied hospitals. Patients were classified according to WHO classification into: mixed cellularity, nodular sclerosis, lymphocyte rich and lymphocyte depletion subtypes. CD15 & CD30 immunophenotype were detected by monoclonal immunostaining method. The frequency was determined in each group and C.I. (confidence interval) was calculated for Iranian population. Result: The studies carried out on 65 patients. Mean age was 31.9±18.1 years. 28 (43.1%) patients were female and 37 (56.9%) were male. CD15 and CD30 was positive in 50 (76.9%) and 58 (89.2%) respectively. Both markers were positive in 46 (70.8%) and were negative in 3 (4.6%). There was no significant relationship between CD15 and CD30 immunostaining and age and gender (p<0.6). Conclusion: It seems that there is a high frequency of immunostaining for CD15 or CD30 in Iranian Hodgkin’s lymphoma patients. These markers are useful in diagnosis of Hodgkin’s lymphoma. However, in CD15 negative , CD30 positive cases, it is better to use additional markers for avoiding misdiagnosis as anaplastic large cell lymphoma. Keywords: Hodgkin’s lymphoma, CD15 & CD30 immunostaining
Full-Text [PDF 108 kb]   (9858 Downloads)    
Type of Study: Original | Subject: Pathology
Received: 2011/02/12 | Published: 2010/11/15

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This Journal is licensed under a Creative Commons Attribution 4.0 International License  | Research in Medicine

Designed & Developed by : Yektaweb